Joe Jimenez (Steffen Schmidt/Keystone via AP Images)
Joe Jimenez forges another big-market, small-cash deal, lining up a kidney disease drug for his latest portfolio startup
Ex-Novartis CEO Joe Jimenez and his partner Mark Fishman put together a $133 million fund to back their play at Aditum, looking to add select …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.